Human VEGF-D Quantikine ELISA Kit
| Name | Human VEGF-D Quantikine ELISA Kit |
|---|---|
| Supplier | R&D Systems |
| Catalog | DVED00 |
| Category | ELISA Kit |
| Prices | $519.00 |
| Sizes | 1 kit |
| Assay Type | Solid Phase Sandwich ELISA |
| Sample Type | Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL) |
| Sensitivity | 31.3 pg/mL |
| Range | 125.0 - 4,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma) |
| Format | 96-well strip plate |
| Applications | ELISA |
| Species Reactivities | Human |
| Description | The Quantikine Human VEGF-D Immunoassay is a 4.5 hour solid phase ELISA designed to measure VEGF-D levels in cell culture supernates, serum, and plasma |
| Gene | FIGF |
| Supplier Page | Shop |
Product images
Product References
Human neural stem cell-induced endothelial morphogenesis requires - Human neural stem cell-induced endothelial morphogenesis requires
Chou CH, Modo M. Sci Rep. 2016 Jul 4;6:29029.
The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell - The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell
Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, Scoazec JY, Negrier S, Simonnet H, Pages G. Cancer Res. 2014 Feb 1;74(3):873-83.
Filarial excretory-secretory products induce human monocytes to produce - Filarial excretory-secretory products induce human monocytes to produce
Weinkopff T, Mackenzie C, Eversole R, Lammie PJ. PLoS Negl Trop Dis. 2014 Jul 10;8(7):e2893.
Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian - Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian
Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Yla-Herttuala S, Anttila M. BMC Cancer. 2014 Sep 23;14:696.
Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary - Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary
Braicu EI, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W, Sehouli J. Cytokine. 2013 Mar;61(3):755-8.
Clinical utility of diagnostic guidelines and putative biomarkers in - Clinical utility of diagnostic guidelines and putative biomarkers in
Chang WY, Cane JL, Blakey JD, Kumaran M, Pointon KS, Johnson SR. Respir Res. 2012 Apr 18;13:34.
Co-expression of alpha9beta1 integrin and VEGF-D confers lymphatic metastatic - Co-expression of alpha9beta1 integrin and VEGF-D confers lymphatic metastatic
Majumder M, Tutunea-Fatan E, Xin X, Rodriguez-Torres M, Torres-Garcia J, Wiebe R, Timoshenko AV, Bhattacharjee RN, Chambers AF, Lala PK. PLoS One. 2012;7(4):e35094.
Prognostic significance of angiogenic factors in uterine cervical cancer. - Prognostic significance of angiogenic factors in uterine cervical cancer.
Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S. Anticancer Res. 2011 Aug;31(8):2589-95.
Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney - Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney
Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, Camposano S, Paolini J, Fennessy F, Lee N, Woodrum C, Manola J, Garber J, Thiele EA. PLoS One. 2011;6(9):e23379.
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor - Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor
Konings IR, de Jonge MJ, Burger H, van der Gaast A, van Beijsterveldt LE, Winkler H, Verweij J, Yuan Z, Hellemans P, Eskens FA. Br J Cancer. 2010 Sep 28;103(7):987-92.